Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Regional variations of rates and determinants of drug resistance mutations in people failing first-line therapy for HIV-1: a substudy from the D2EFT phase 3b/4 clinical trial.
Billal Musah Obeng, Jolie Hutchinson, Ansari Shaik, Ploenchan Chetchotisakd, Iskandar Azwa, Wahyu Nawang Wulan, Nagalingeswaran Kumarasamy, Marcelo Wolff, José Bruguera, Marcelo Losso, Richard Kaplan, Mariama Sadjo Diallo, Nnakelu Eriobu, Godfrey Musoro, July Kumalawati
Published: 202610.1093/cid/ciaf739
Abstract
INTRODUCTION: D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) was a phase 3b/4 randomized clinical trial designed to assess second-line treatment options systematically. This sub-study evaluated the distribution of drug resist…
Preview only. Read the full abstract at the source